Omission of adverse event reporting on finerenone
AbstractWe wish to describe the omission of adverse event reporting on
finerenone in a recently published trial. We suspect that this case
illustrates the tip of an iceberg of underreporting of adverse events in
clinical trials. We propose as a requirement in clinical trials, to have
routine direct reporting by patients for safety monitoring.